Physiologically Based Biopharmaceutics Modeling (PBBM) is no longer a peripheral, exploratory tool and has emerged as a central pillar in modern formulation development and an increasingly important component of Model-Informed Drug Development (MIDD) and regulatory decision-making.
By leveraging mechanistic models to link in-vitro dissolution data with in-vivo pharmacokinetics (PK), sponsors can successfully connect drug product performance to clinical outcomes, thereby informing formulation development, reducing unnecessary clinical experimentation, optimizing drug products, and enhancing patient safety [4, 5].
At its core, PBBM addresses a critical question in drug development: will a difference observed in vitro actually matter in the patient? As its use expands across development and regulatory decision-making, model credibility, transparency, and fitness for purpose have become increasingly important [3].
Over the past decade, biopharmaceutics has progressively evolved beyond traditional, empirical In-Vitro-In-Vivo Correlations (IVIVC) toward more mechanistic PBBM approaches. PBBM provides a quantitative bridge across the continuum
The quantitative bridge established by PBBM
This represents an important shift. An in vitro difference does not necessarily translate into a clinically meaningful difference; conversely, changes in formulation, particle size, manufacturing process, or dissolution behavior may meaningfully affect exposure for certain compounds. PBBM provides a framework to understand when these differences matter.
The United States Food and Drug Administration (FDA) has formalized its expectations through specific guidance on the use of PBBM to support biopharmaceutics applications [1]. Similarly, the European Medicines Agency (EMA) and other global health authorities engage with sponsors on the use of mechanistic modeling approaches to support drug development and regulatory decisions [2].
A credible PBBM model must be rigorously parameterized, highly transparent and mechanistically sound for its intended context of use.
A fundamental principle is that a PBBM model relies heavily on the quality of its inputs. Sponsors should generate robust, biorelevant in vitro dissolution data rather than relying solely on quality control (QC) media [5].
The model must accurately capture the relevant physicochemical properties of the active pharmaceutical ingredient (API), such as solubility and permeability, as well as dissolution, precipitation, and particle characteristics where relevant and dynamically link them to human gastrointestinal physiology.
The level of validation required should be aligned with the intended Context of Use and the impact of the decision supported by the model [3].
If a PBBM model is used to waive a pivotal clinical bioequivalence (BE) study, it faces the highest level of scrutiny. Sponsors are expected to rigorously assess predictive performance by validating the model against clinical PK data from multiple formulations with varying release rates. Predictive accuracy is often evaluated using predefined acceptance criteria for PK parameters like Cmax and AUC.
For lower-impact applications, such as early formulation selection or optimization, the required level of evidence may be different. In all cases, sensitivity and uncertainty analyses can help identify the parameters driving model predictions and guide the generation of additional experimental data.
a One of the most valuable applications of PBBM is its ability to define a 'safe space', setting the boundaries of in vitro dissolution profiles within which clinically meaningful changes in systemic exposure are not expected. This creates a direct connection between:
The safe space causal chain
These boundaries can be explored through virtual trials [1, 3] and can support formulation development, clinically relevant specifications, manufacturing changes, and lifecycle management. Importantly, the limits of the safe space and the uncertainty associated with predictions outside the validated range should be clearly communicated..
PBBM can create value throughout drug product development, from early formulation selection to post-approval lifecycle management.
PBBM can help identify the physicochemical and formulation attributes most likely to limit absorption. For example, simulations can determine whether improving dissolution is likely to increase exposure or whether permeability, precipitation, or another mechanism is the dominant limitation. This can help prioritize experiments and reduce empirical trial-and-error.
PBBM can connect dissolution performance to systemic exposure and help define clinically relevant specifications, ensuring that acceptable product variability is not expected to meaningfully affect clinical performance [1].
PBBM is a valuable tool for life-cycle management. VBE can help to bridge formulation changes such as moving from a clinical trial formulation to a commercial one, or altering manufacturing sites, while potentially reducing the need for additional clinical BE studies when appropriately justified [3].
PBBM can bridge the gap between fasted and fed states by mechanistically modeling gastrointestinal transit times, bile salt secretion, and micellar solubilization [4]. Beyond predicting whether a food effect exists, PBBM can help explain the mechanisms driving the change in exposure.
To successfully maximize the scientific and regulatory value of PBBM, biopharmaceutics teams and pharmacometricians should adopt the following best practices:
N'attendez pas la soumission de la demande d'autorisation de mise sur le marché (NDA/BLA) pour introduire un modèle PBBM complexe. L'introduction précoce de la PBBM permet au modèle d'évoluer parallèlement au développement clinique et à celui de la formulation. Utilisez les réunions avec les agences réglementaires, le cas échéant, pour obtenir un alignement précoce sur la stratégie de modélisation, le choix des milieux biopertinents et l'application réglementaire visée.
Just as clinical trials require careful planning, PBBM efforts should be governed by a pre-specified plan. Bottom-up parameters (like permeability and solubility) must be carefully measured, while top-down optimization should be scientifically justified and transparently documented [2].
A successful PBBM strategy is rarely the product of a single scientist. It requires tight integration between formulators, analytical chemists generating dissolution data, and the modelers building the framework, and clinical pharmacologists interpreting the impact on exposure. The final modeling strategy should translate complex mechanistic outputs into clear, actionable drug development insights.
PBBM is also most powerful when integrated into a broader MIDD strategy. Together with PBPK, population PK, and PK/PD or exposure-response modeling, it can contribute to a quantitative continuum:
The MIDD quantitative continuum
Within this continuum, PBBM provides a particularly important bridge between pharmaceutical sciences and clinical pharmacology.
As drug product development becomes increasingly complex, PBBM offers a scientifically rigorous pathway to understand how drug product characteristics translate into in vivo performance, de-risk formulation and manufacturing changes, and support more informed development decisions.
When appropriately developed and applied, PBBM can support formulation optimization, clinically relevant dissolution specifications, safe-space definition, virtual bioequivalence, food-effect assessment, formulation and manufacturing changes, regulatory strategy, and lifecycle management.
Yesterday's question
« Does this drug product look different in vitro? »
The question that matters
« Will this difference matter in vivo? »
That connection between drug product performance and clinical relevance is where PBBM can have its greatest impact on modern drug development.
The PhinC team supports sponsors in building, validating and documenting their PBBM and PBPK models — from formulation strategy to regulatory submission.
Search expertise, case studies, publications, resources and more.
